Suna Çelen

Suna Çelen

Auto-generated profile, based on publicly available information

Suna Çelen

Bahçeşehir University, Faculty of Medicine, MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit, İstanbul, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SÇSafiye Suna Çelen
Safiye Suna Çelen
SZSuleimen Zhumatayev
Suleimen Zhumatayev
KYKoray Yalcin
Koray Yalcin
MKManolya Kara
Manolya Kara
MSMurat Sütçü
Murat Sütçü
MYM. Akif Yeşilipek
M. Akif Yeşilipek
Background. Ralstonia pickettii is an aerobic Gram-negative non-fermentative bacillus. It is an opportunistic pathogen that has recently prompted nosocomial outbreaks. Although it has low virulence, it can cause a wide range of invasive diseases in immunosuppressive patients. The characteristics of R. pickettii-related central line-associated bloodstream infection (CLABSI) outbreak in pediatric hematopoietic stem cell transplant (HSCT) recipients are presented in this study. Materials and Methods. This was a single-center, retrospective analysis conducted at Bahcesehir University Goztepe Medicalpark Hospital . The clinical and laboratory characteristics of twelve children with Ralstonia-related CLABSIs were analyzed. Results. Of the twelve patients with R. pickettii growth, seven were female. The median age was 12.1 (2-17) years. Autologous HSCT was performed in two of the patients and allogeneic HSCT was performed in ten patients for both malignant and non-malignant diseases. In the conditioning regimens, all patients were given myeloablative therapy. Clinical sepsis was the most common presentation. As a result of the investigations, R. pickettii growth was observed in saline solutions. All cases were successfully treated with the appropriate antibiotic regimen and the bacteria was not found in repeat cultures. Catheter removal was required in two patients. Mortality was not observed in any patient as the outcome of the infection episode. Conclusion. The detection and control of the infectious source are critical in pediatric HSCT patients with severe immunosuppression, as medical equipment-related outbreaks can be life-threatening.

4 April 2024 in Indian Journal of Otolaryngology and Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
SZSuleimen Zhumatayev
Suleimen Zhumatayev
SCSafiye Suna Celen
Safiye Suna Celen
MKManolya Kara
Manolya Kara
ASAyse Adin Selcuk
Ayse Adin Selcuk
BBBetül Bozkurt
Betül Bozkurt
KYKoray Yalcin
Koray Yalcin

15 August 2025 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
VUVedat Uygun
Vedat Uygun
KYKoray Yalcin
Koray Yalcin
HDHayriye Daloğlu
Hayriye Daloğlu
SÖSeda Öztürkmen
Seda Öztürkmen
SÇSuna Çelen
Suna Çelen
AYAkif Yeşilipek
Akif Yeşilipek
Background: It is uncertain whether hematopoietic stem cell transplantation (HSCT), versus standard enzyme replacement therapy (ERT), is effective for type VI mucopolysaccharidosis (MPS VI).Purpose: New related advances in HSCT prompted an examination of the transplant procedures performed in a recent cohort.Methods: This single-center retrospective study reviewed the medical records of 17 pediatric patients with MPS VI who underwent allogeneic HSCT in 2021–2023. All conditioning regimens were myeloablative. Engraftment days, complications, and survival data were recorded. As follow-up was short, we recorded only 6-minute walk test distance before versus after HSCT.Results: The patients underwent transplantation at a median of 6-year postdiagnosis. All were engrafted and had a full or mixed chimerism. Enzyme levels were within normal ranges. Walking tests of all evaluable patients improved at a median 9-month follow-up.Conclusion: HSCT aims to improve the disease and provides a permanent solution at the enzyme level, eliminating ERT. Our study showed that HSCT, a less expensive and permanent treatment option, should be offered to patients with MPS VI.

14 September 2022 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
KYKoray Yalcin
Koray Yalcin
HTHatice Turanoglu
Hatice Turanoglu
AGAysenur Gencalp
Aysenur Gencalp
MDMustafa Kemal Demir
Mustafa Kemal Demir
SCSafiye Suna Celen
Safiye Suna Celen
GKGulsun Karasu
Gulsun Karasu

1 September 2022 in The Journal of Pediatric Research
Verified
Journal Article
Open access
KYKoray Yalcin
Koray Yalcin
DPDayanat Pashayev
Dayanat Pashayev
SÇSuna Çelen
Suna Çelen
SZSuleimen Zhumatayev
Suleimen Zhumatayev
GKGülsün Karasu
Gülsün Karasu
AYAkif Yeşilipek
Akif Yeşilipek

30 March 2022 in LLM Dergi
Verified
Journal Article
Closed access
KYKoray Yalcin
Koray Yalcin
EEErsin Erhal
Ersin Erhal
MYMelih Yıldırım
Melih Yıldırım
BKBurcu Kömoğ
Burcu Kömoğ
SÇSuna Çelen
Suna Çelen
AYAkif Yeşilipek
Akif Yeşilipek